ArticleHealth and quality of life outcomes2026
Quality of life scores using SF-12 and SF-36v2 questionnaires for patients with multidrug-resistant tuberculosis in Vietnam.
Article in Health and quality of life outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe health-related quality of life (QoL) assessed by the 12-item Short Form (SF-12) offers a time-efficient alternative to the 36-item version 2 (SF-36 v2). This study aimed to compare the performance of SF-12 and SF-36 v2 among patients with rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) in Vietnam.
methodsA cross-sectional survey was conducted among RR/MDR-TB patients treated in seven provinces between October 2020 and March 2023. Participants completed the SF-36 v2 questionnaire at enrollment. Physical (PCS) and mental component summary (MCS) scores were compared between SF-12 and SF-36 v2. Linear regression assessed the ability of PCS-12 and MCS-12 to predict PCS-36 and MCS-36. Discriminative ability was assessed via receiver operating characteristic (ROC) curves.
resultsThis study included 565 participants with a median age of 45.4 years (IQR 44.2–46.5) and a male proportion of 71.7%. 64.1% (362/565) had PCS-36 and 88.3% (499/565) had MCS-36 scores well below and below population norms. The mean scores of PCS-12 and MCS-12 were higher than those of PCS-36 (45.1; 95% CI 44.1–46.1 vs. 43.6; 95% CI 43.1–44.1), and MCS-36 (45.2; 95% CI 43.8–46.6 vs. 34.6; 95% CI 33.9–35.4; p < 0.001), respectively. The Intraclass Correlation Coefficients (ICCs) between PCS and MCS scores of SF-12 and SF-36 v2 were 0.6 (95% CI: 0.5–0.6) and 0.5 (95% CI: 0.4–0.5) respectively. The AUC values for comparing the performance of PCS and MCS of two scales were 0.89 and 0.99, respectively. We found the excellent linear correlation between PCS-12 and PCS-36 (r = 0.8; p < 0.001) and between MCS-12 and MCS-36 scores (r = 0.9; p < 0.001).
conclusionSF-12 had moderate correlation to SF-36 v2 for QoL assessment in RR/MDR-TB patients, though it tends to overestimate QoL in older and male individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.